Dr. Reddy’s Laboratories Ltd (RDY) Set to Announce Earnings on Tuesday
Dr. Reddy’s Laboratories Ltd (NYSE:RDY) will be releasing its earnings data after the market closes on Tuesday, October 31st.
Shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) traded down 0.28% during midday trading on Tuesday, reaching $36.15. The company’s stock had a trading volume of 91,566 shares. The stock’s 50-day moving average is $35.63 and its 200 day moving average is $37.98. Dr. Reddy’s Laboratories Ltd has a 12 month low of $29.83 and a 12 month high of $50.10. The stock has a market capitalization of $5.99 billion, a P/E ratio of 33.75 and a beta of 0.36.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/24/dr-reddys-laboratories-ltd-rdy-set-to-announce-earnings-on-tuesday.html.
RDY has been the topic of a number of recent analyst reports. BidaskClub lowered Dr. Reddy’s Laboratories from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 8th. CLSA lowered Dr. Reddy’s Laboratories from an “underperform” rating to a “sell” rating in a research note on Friday, July 28th. Jefferies Group LLC reiterated a “sell” rating and issued a $31.62 price objective on shares of Dr. Reddy’s Laboratories in a research note on Sunday, September 3rd. Zacks Investment Research upgraded Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 26th. Finally, Morgan Stanley upgraded Dr. Reddy’s Laboratories from an “equal weight” rating to an “overweight” rating in a research note on Thursday, September 21st. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Dr. Reddy’s Laboratories has a consensus rating of “Hold” and a consensus target price of $31.62.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).
Receive News & Ratings for Dr. Reddy's Laboratories Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories Ltd and related companies with MarketBeat.com's FREE daily email newsletter.